Equities

Henan Lingrui Pharmaceutical Co Ltd

600285:SHH

Henan Lingrui Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)25.09
  • Today's Change0.44 / 1.78%
  • Shares traded6.24m
  • 1 Year change+54.40%
  • Beta1.0895
Data delayed at least 15 minutes, as of Jun 14 2024 08:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.

  • Revenue in CNY (TTM)3.43bn
  • Net income in CNY614.24m
  • Incorporated1999
  • Employees2.53k
  • Location
    Henan Lingrui Pharmaceutical Co LtdNo.666, Jiangjun Road, Xinxian CountyXINYANG 465550ChinaCHN
  • Phone+86 3 762973569
  • Fax+86 3 762987888
  • Websitehttp://www.lingrui.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mabwell Shanghai Bioscience Co Ltd191.35m-1.02bn12.76bn1.49k--5.30--66.66-2.55-2.550.47896.020.04120.047216.79128,337.60-22.02-37.61-26.37-45.9596.8481.54-534.78-2,112.261.96--0.442--361.0327.88-10.28--17.35--
Changchun BCHT Biotechnology Co1.92bn543.19m12.99bn1.24k23.873.18--6.781.321.324.649.880.41160.84591.551,543,550.0011.679.9514.1412.8189.9086.6328.3624.032.03--0.015810.5570.3012.36175.9831.3721.04--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.18bn208.25m13.09bn1.55k62.865.82--11.080.97690.97695.5410.550.37431.214.71764,598.406.695.869.157.5963.1555.4117.8717.201.0833.770.335627.5958.6932.2426.2029.9927.32--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.43bn523.43m13.26bn8.41k25.541.86--2.060.2020.2022.492.780.55682.394.60764,058.905.026.777.2510.5054.3663.249.0211.101.5340.710.145942.3212.20-0.826765.20-6.21-11.645.92
Zhejiang Jiuzhou Pharmaceutical Co Ltd5.25bn989.32m13.46bn4.88k13.561.54--2.561.101.105.849.690.45231.874.361,076,055.008.5210.1011.0713.6935.8034.6418.8316.262.07--0.181640.791.4424.2912.2045.7432.1420.11
Sunshine Guojian Pharmcutcl Shngh Co Ltd1.07bn352.22m13.47bn965.0038.252.70--12.550.5710.5711.748.090.20781.149.251,112,527.006.611.326.931.4177.8580.7431.816.556.66--0.018.2522.84-2.35497.63-4.4421.22--
Liaoning Cheng Da Co Ltd11.18bn17.48m14.03bn3.36k705.380.4809--1.260.0130.0137.3419.070.23584.416.493,330,121.00-0.53663.59-0.76445.2116.0314.15-2.289.890.7792--0.283415.93-25.97-10.97-80.95-21.267.04--
Anhui Huaheng Biotechnology Co Ltd2.04bn454.44m14.20bn1.69k31.277.42--6.962.882.8812.9412.150.61965.598.041,205,674.0013.7116.7421.5922.4138.4939.2122.1322.340.4552155.980.455225.2036.6335.7240.3242.8482.09--
Henan Lingrui Pharmaceutical Co., Ltd.3.43bn614.24m14.23bn2.53k23.024.82--4.151.091.096.095.210.72462.0413.841,356,471.0012.9710.6821.2716.5671.7474.4217.9014.921.26--0.012272.8010.3110.0322.0918.49-16.4739.77
KPC Pharmaceuticals Inc7.65bn432.35m14.60bn5.05k33.702.70--1.910.57250.572510.157.150.80212.482.621,513,702.004.635.427.769.1343.1243.685.775.701.4653.930.168835.75-6.991.6416.055.79-21.3314.87
Shanghai Shyndec Pharmaceutical Co Ltd11.78bn843.91m14.66bn11.61k17.091.15--1.240.63940.63948.959.480.60693.086.611,014,487.005.754.858.508.1737.0943.009.487.031.82--0.105717.52-6.861.2910.21-0.3897-2.210.00
BrightGene Bio-Medical Technology Co Ltd1.21bn195.77m14.75bn1.16k76.416.08--12.140.45690.45692.875.750.24631.694.431,051,700.003.436.534.297.9354.9256.9313.9319.901.454.860.478729.3115.9423.68-15.5122.5629.13--
Suzhou Zelgen Biopharmaceuticals Co Ltd386.57m-260.85m15.06bn867.00--9.45--38.95-1.00-1.001.496.020.16210.25943.75445,874.00-11.74-27.13-20.82-39.2092.2992.75-72.40-220.712.15--0.3842--27.83211.8139.08--41.38--
Data as of Jun 14 2024. Currency figures normalised to Henan Lingrui Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

14.42%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 31 Dec 202332.80m5.59%
First Seafront Fund Management Co., Ltd.as of 30 Jun 202313.82m2.36%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 202311.26m1.92%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 20236.32m1.08%
China Southern Asset Management Co., Ltd.as of 31 Dec 20236.16m1.05%
Taikang Asset Management Co. Ltd.as of 31 Dec 20234.98m0.85%
China Universal Asset Management Co., Ltd.as of 31 Dec 20232.91m0.50%
Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 20232.21m0.38%
Lion Fund Management Co., Ltd.as of 31 Dec 20232.16m0.37%
China Asset Management Co., Ltd.as of 31 Dec 20231.95m0.33%
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.